19 October 2021 - Enhertu has been approved for provisional registration.

Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2-based regimens.

Read Australian prescription medicine decision summary for Enhertu